Diabetes Insipidus

Diagnostic Approach to Polydipsia and Polyuria

Clinical Evaluation

• Pathologic polyuria is defined as a urine output exceeding 2 L/m2/day or 5 mL/kg/hr.
• A careful history is the first step and must quantify the child's daily fluid intake and output, establish the voiding pattern, and assess for nocturia and primary or secondary enuresis.
• In infants, clinical presentation may be non-specific, often including irritability, failure to thrive, vomiting, and intermittent fever.
• Long-standing ingestion and excretion of large volumes of water can lead to complications such as nonobstructive hydronephrosis, hydroureter, and megabladder.
• A complete physical examination must be conducted to establish the patient's hydration status.
• The physician should actively search for evidence of visual and central nervous system dysfunction, as well as for clinical signs of other pituitary hormone deficiencies (e.g., midline facial defects, optic nerve hypoplasia, or microphallus).

Initial Laboratory Investigations

• If pathologic polyuria or polydipsia is present, initial outpatient evaluation requires simultaneous testing of blood and urine.
• Serum parameters to be obtained include osmolality, sodium, potassium, blood urea nitrogen, creatinine, glucose, hemoglobin A1c, and calcium.
• Urinalysis must include measurement of urine osmolality, specific gravity, and glucose determination.
• The diagnosis of diabetes insipidus (DI) is firmly established if the serum osmolality is elevated (>300 mOsm/kg H2O) or serum sodium is high (>146 mEq/L) in the presence of a low urine osmolality (<300 mOsm/kg) and a urine specific gravity of <1.005.
• Conversely, diabetes insipidus is highly unlikely if the serum osmolality is <270 mOsm/kg H2O or if the urine osmolality is >600 mOsm/kg.
• Metabolic causes of polyuria, such as diabetes mellitus (osmotic diuresis), hypercalcemia, and hypokalemia (which can cause acquired nephrogenic DI), must be excluded based on these initial labs.

The Water Deprivation Test

• The water deprivation test is indicated in children with pathologic polyuria and polydipsia who have low urinary osmolality but a normal plasma osmolality (<300 mOsm/kg H2O, but >270 mOsm/kg H2O) at baseline.
• The aim of the test is to increase plasma osmolality above 300 mOsm/kg (or serum sodium above 146 mEq/L) to provide a maximal osmotic stimulus for arginine vasopressin (AVP) release and subsequent renal concentration.
• This test is contraindicated and not required if the patient already presents with hypernatremia or a plasma osmolality >300 mOsm/kg.
• Because of the significant risk of dehydration, the test must be performed on an inpatient basis.
• The test is initiated early in the morning after a maximally tolerated overnight fast, depending on the child's outpatient history.
• The child's baseline weight is recorded, and a target weight loss limit (5% of total body weight) is calculated.
• Body weight, urine output, vital signs, and both urine and blood osmolality are monitored hourly.
• The test is immediately terminated if any of the following occur: urine osmolality increases above 750 mOsm/kg or specific gravity exceeds 1.010 (which excludes DI); serum sodium rises above 146 mEq/L; weight loss exceeds 5% (indicating high risk of severe dehydration); or vital signs indicate hypovolemia.
• If the serum osmolality rises above 300 mOsm/kg but the urine osmolality remains below 300 mOsm/kg (or <600 mOsm/kg), the diagnosis of DI is confirmed, and the test proceeds to the vasopressin response phase.

Vasopressin Response Test

• To differentiate between central DI (AVP deficiency) and nephrogenic DI (AVP resistance), a formal vasopressin response test is conducted at the conclusion of the water deprivation test.
• Aqueous vasopressin (Pitressin) is administered via subcutaneous injection at a dose of 1 U/m2 or 0.1 unit/kg.
• Urine osmolality and volume are measured one hour after the injection.
• An increase in urine osmolality by more than 50% of the baseline level (or a doubling of the osmolality) is diagnostic of central DI.
• A smaller increase (less than a twofold rise) or a lack of response suggests nephrogenic DI.
• Desmopressin (DDAVP) should generally be avoided for this specific test because its longer duration of action has been associated with water intoxication in small children in this setting.

Role of Copeptin in Diagnosis

• Copeptin, the carboxy-terminus of the vasopressin precursor, is a highly stable surrogate marker that is increasingly replacing direct vasopressin measurement.
• A baseline copeptin level above 20 pmol/L (or >21.4 pmol/L in some assays) in the setting of polyuria and hypernatremia definitively confirms nephrogenic DI without the need for a water deprivation test.
• For differentiating central DI from primary polydipsia, hypertonic saline (3% saline) infusion can be used to raise the plasma sodium level above 150 mmol/L to provide an osmotic stimulus for copeptin secretion.
• At this stimulated hyperosmolar state, a copeptin level <= 4.9 pmol/L indicates central DI, whereas a level >4.9 pmol/L indicates primary polydipsia. This hypertonic saline test demonstrates higher diagnostic accuracy (96.5%) compared to the traditional indirect water deprivation test (76.6%).

Etiological Evaluation and Imaging

• Once central DI is confirmed, magnetic resonance imaging (MRI) of the hypothalamic-pituitary region and a complete anterior pituitary hormone evaluation must be performed.
• On a normal T1-weighted MRI, the posterior pituitary is visible as an area of enhanced brightness (the "bright spot"). This bright spot is diminished or absent in both central and nephrogenic DI.
• Thickening of the pituitary stalk on MRI strongly suggests an infiltrative disorder like Langerhans cell histiocytosis or lymphocytic infundibuloneurohypophysitis.
• Brain tumors, particularly germinomas and pinealomas, can cause central DI and may initially be too small to be detected on MRI; therefore, serial MRIs and quantitative measurement of tumor markers (alpha-fetoprotein and beta-human chorionic gonadotropin) are required in children with idiopathic central DI.
• Evaluation of nephrogenic DI requires renal imaging (ultrasonography) to check for obstructive uropathy or cystic diseases, and screening for genetic defects (e.g., AVPR2 or AQP2 mutations) if congenital onset is suspected.

Management of Central Diabetes Insipidus

Fluid Therapy and Dietary Management in Infants

• Neonates and young infants with central DI are best managed solely with fluid therapy because their obligate requirement for large volumes of nutritive fluid (~3 L/m2/24 hr) makes the use of vasopressin analogs highly dangerous due to the risk of life-threatening hyponatremia.
• A reduced solute load diet is essential to minimize the necessary urine volume required to excrete the daily solute load.
• Human milk is ideal for this purpose as it has a low renal solute load (75 mOsm/kg H2O) compared to cow's milk (230 mOsm/kg H2O). Specialized formulas with low renal solute loads (e.g., Similac PM 60/40) are also utilized.
• Supplemental free water (e.g., 20 to 30 mL for every 120 to 160 mL of formula) or dilution of the formula may be needed depending on the severity of the DI.
• Thiazide diuretics (chlorothiazide, 5-10 mg/kg/dose given twice or thrice daily) and/or amiloride can be added to facilitate proximal tubular sodium and water reabsorption, thereby decreasing total oral fluid requirements.
• If medication is strictly required, parenteral desmopressin (0.02-0.08 mcg/dose) or buccal administration of a diluted intranasal formulation (1-5 mcg twice daily) has been used successfully, though this requires extreme caution and frequent sodium monitoring.

Pharmacological Therapy in Older Children

• In older children with an intact thirst mechanism, the treatment of choice is the synthetic vasopressin analog desmopressin (DDAVP), which possesses high antidiuretic potency with a prolonged duration of action and lacks pressor activity.
• Desmopressin is available in intranasal, sublingual, and oral tablet formulations.
• The intranasal preparation (10 µg/0.1 mL) is typically initiated at a dose of 2.5 to 10 µg every 12 hours, titrated according to urine output.
• Oral DDAVP tablets require a 10- to 20-fold increase in dosage compared to the intranasal route; typical oral dosages range from 25 to 300 µg every 8 to 12 hours.
• To prevent dangerous water intoxication and dilutional hyponatremia, the dosage must be carefully titrated, and patients must experience at least one hour of "urinary breakthrough" (a period where the antidiuretic effect wanes and polyuria resumes) before the next dose is administered.
• Patients should be educated to drink fluids only in response to the sensation of thirst.

Management of Acute Postoperative Central DI

• Central DI following neurosurgery (e.g., for craniopharyngioma) may exhibit a classic "triphasic response": an initial transient DI phase (12-48 hours), followed by a phase of syndrome of inappropriate antidiuresis (SIAD) (lasting up to 10 days), and finally permanent DI.
• Acute postoperative DI is best managed with a continuous intravenous infusion of synthetic aqueous vasopressin (Pitressin), as its short half-life (5-10 minutes) allows for rapid dose adjustments.
• A typical starting dosage is 0.5 to 1.5 mU/kg/hr, titrated upward to maintain a urine output of less than 2 mL/kg/hr.
• During continuous vasopressin infusion, total fluid intake must be strictly limited (typically to 1 L/m2/24 hr or two-thirds maintenance) to prevent hyponatremia.
• Desmopressin (DDAVP) is contraindicated in the acute postoperative management phase because its prolonged half-life (8-24 hours) substantially increases the risk of water intoxication and masks the emergence of the SIAD phase.
• Alternatively, a fluid-matching protocol without antidiuretic medication can be used. This involves replacing urine output hourly with 5% dextrose in water (up to a maximum of 120 mL/m2/hr) on top of a basal infusion of 5% dextrose in 0.25 normal saline. This prevents hyponatremia but requires intensive monitoring.

Management of Adipsic Central DI

• Lesions affecting the hypothalamic osmosensors can result in an absent thirst mechanism (adipsia), putting the patient at extreme risk for severe, life-threatening hypernatremia.
• Management is highly complex and requires administering a fixed daily dose of DDAVP combined with a strictly prescribed and controlled daily fluid intake.
• Strict, frequent monitoring of fluid balance, daily body weight, and plasma sodium levels is mandatory to prevent both hypernatremia and hyponatremia.

Management of Nephrogenic Diabetes Insipidus

Nutritional and Fluid Management

• The primary goal is to ensure the intake of adequate calories to permit normal linear growth while preventing severe episodes of dehydration.
• Patients require a diet with the highest possible ratio of caloric content to osmotic load (sodium <1 mmol/kg/24 hr).
• Restricting dietary sodium and protein limits the obligate renal solute load, thereby minimizing the volume of water the kidneys must excrete.

Pharmacological Interventions

• For acquired nephrogenic DI, the primary intervention is to correct or eliminate the underlying cause, such as discontinuing offending medications (e.g., lithium, demeclocycline) or correcting metabolic derangements like hypercalcemia and hypokalemia.
• For congenital nephrogenic DI, thiazide diuretics (e.g., hydrochlorothiazide) are the mainstay of pharmacological therapy.
• Thiazides induce a state of mild intravascular volume depletion, which leads to a compensatory decrease in the glomerular filtration rate and a subsequent enhancement of sodium and water reabsorption in the proximal convoluted tubule, effectively decreasing total urine output.
• Because thiazides can cause hypokalemia, they are frequently combined with potassium-sparing diuretics like amiloride. Amiloride is particularly beneficial in lithium-induced nephrogenic DI as it blocks lithium uptake by renal epithelial cells.
• Prostaglandin synthesis inhibitors, specifically indomethacin, can be added to the thiazide regimen. Indomethacin further reduces urine output (by 50-70%) by enhancing proximal tubular sodium and water reabsorption, though its potential for nephrotoxicity requires careful monitoring.
• In patients with specific AVPR2 genetic defects that only partially reduce the receptor's binding affinity for vasopressin, high-dose DDAVP therapy combined with indomethacin has been reported to provide therapeutic benefit.